Novo Holdings leads $50 million investment in MedGenome to accelerate expansion into new markets and deepen product offerings
The investment will increase access to genetic testing across emerging markets and contribute to the most comprehensive global genomic dataset.
- The investment will increase access to genetic testing across emerging markets and contribute to the most comprehensive global genomic dataset.
- "The success that the MedGenome team has achieved over the last decade is extraordinary," said Amit Kakar at Novo Holdings.
- LeapFrog Investments, which led a $55 million investment round in MedGenome in April 2020, will be adding to its investment alongside Novo, as well as existing investor, Sofina.
- Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.